This website uses cookies. By using this website, you agree to our Cookie Policy.
October 15, 2019
Cadwalader advised HealthCare Royalty Partners in connection with a revenue interest financing transaction with Karyopharm Therapeutics for up to $150 million to support the ongoing development and commercialization of XPOVIOTM (selinexor), Karyopharm’s oral SINE compound that is currently marketed in the United States for the treatment of patients with heavily pretreated multiple myeloma.
The Cadwalader team was led by partner Ira Schacter and included Joo Kim.
